Annals of Surgical Oncology

, Volume 17, Issue 11, pp 3068–3075 | Cite as

Role of MMP-3 and MMP-9 and Their Haplotypes in Risk of Bladder Cancer in North Indian Cohort

  • Priyanka Srivastava
  • Anil Mandhani
  • Rakesh Kapoor
  • Rama D. Mittal
Translational Research and Biomarkers



Matrix metalloproteinases (MMPs) play critical roles in cancer development and progression. Nonsynonymous single nucleotide polymorphisms (SNPs) in functional domain of MMP-3 and MMP-9 contribute appreciably to cancer predisposition and aggression. To test this proposition we examined whether six SNPs of the MMP-3 and MMP-9 genes are associated with risk of bladder cancer (BC) in a North Indian population.


Six SNPs of MMP-3 and MMP-9 were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in a case–control study including 200 BC patients and 200 age/gender/ethnicity-matched controls.


Increased risk for BC susceptibility was observed in MMP-3 (1171) 5A/5A [P = 0.022; odds ratio (OR), 3.46; 95% confidence interval (CI), 1.20–9.98], MMP-9 (Q279R) QQ (P = 0.048; OR, 1.92; 95%CI, 1.01–3.66), MMP-9 (P574R) PR (P < 0.001; OR, 2.62; 95%CI, 1.71–4.03) and PR + RR (P < 0.001; OR, 2.59; 95%CI, 1.72–3.91) genotypes, and in R allele (P < 0.001; OR, 2.05; 95%CI, 1.47–2.85). Furthermore, significant association between MMP-9 Q279R, P574R polymorphism and smoking was observed in BC risk. Haplotype analysis too revealed significant association with 5A-A-G of MMP-3 haplotype (P = 0.022; OR, 1.99; 95%CI, 1.11–3.60) and with R-R (P = 0.001; OR, 2.00; 95%CI, 1.35–2.97) and Q-R (P < 0.001; OR, 2.97; 95%CI, 1.65–5.37) of MMP-9 haplotype. Genotype 5A/6A of MMP-3-1171 showed borderline risk and high recurrence-free survival in Bacillus Calmette–Guérin (BCG)-treated non-muscle-invasive BC (NMIBC) patients (log-rank P = 0.025).


Our data suggested that MMP-3-1171 5A/5A and MMP-9 (Q279R) QQ, MMP-9 (P574R) PR, PR + RR, and R allele are associated with high risk of BC.



The study was funded by Department of Science and Technology, New Delhi, Govt. of India.


  1. 1.
    Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999;189:300–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10:415–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Natl Rev Cancer 2002;2:161–74.CrossRefGoogle Scholar
  5. 5.
    Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol. 1996;28:123–36.CrossRefPubMedGoogle Scholar
  6. 6.
    Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 2001;57:675–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, et al. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer. 1996;78:2379–87.CrossRefPubMedGoogle Scholar
  8. 8.
    Zinzindohoué F, Lecomte T, Ferraz JM, et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res. 2005;11:594–9.PubMedGoogle Scholar
  9. 9.
    Grieu F, Li WQ, Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat. 2004;88:197–204.CrossRefPubMedGoogle Scholar
  10. 10.
    Colombel M, Soloway M, Akaza H. Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol Suppl. 2008;7:618–26.CrossRefGoogle Scholar
  11. 11.
    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16: 1215.CrossRefPubMedGoogle Scholar
  12. 12.
    Shibata N, Ohnuma T, Higashi S, et al. Genetic association between matrix metalloproteinase MMP-9 and MMP-3 polymorphisms and Japanese sporadic Alzheimer’s disease. Neurobiol Aging. 2005;26:1011–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Wu J, Zhang L, Luo H, Zhu Z, Zhang C, Hou Y. Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma. DNA Cell Biol. 2008;27:553–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang J, Jin X, Fang S, et al. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis. 2005;26:1748–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996;271:13055–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995;73:209–15.CrossRefPubMedGoogle Scholar
  17. 17.
    Hinoda Y, Okayama N, Takano N, et al. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer. 2002;102:526–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002;8:3820–3.PubMedGoogle Scholar
  19. 19.
    St-Pierre Y, Van Themsche C, Estève PO. Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr Drug Targets Inflamm Allergy. 2003;2:206–15.CrossRefPubMedGoogle Scholar
  20. 20.
    Matsumura S, Oue N, Nakayama H, et al. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol. 2005;131:19–25.CrossRefPubMedGoogle Scholar
  21. 21.
    Hu Z, Huo X, Lu D, et al. Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res. 2005;11:5433–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Cotignola J, Reva B, Mitra N, et al. Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma. BMC Med Genet. 2007;8:10.CrossRefPubMedGoogle Scholar
  23. 23.
    Awakura Y, Ito N, Nakamura E, et al. Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett. 2006;241:59–63.CrossRefPubMedGoogle Scholar
  24. 24.
    Tang Y, Zhu J, Chen L, Chen L, Zhang S, Lin J. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer. Clin Cancer Res. 2008;14:2870–7.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  • Priyanka Srivastava
    • 1
  • Anil Mandhani
    • 1
  • Rakesh Kapoor
    • 1
  • Rama D. Mittal
    • 1
  1. 1.Department of Urology and Renal TransplantationSanjay Gandhi Post Graduate Institute of Medical SciencesLucknowIndia

Personalised recommendations